Jeffrey V. Lazarus
@JVLazarus
Committed to people-centred health systems. Director #SLDthinktank. Professor @CUNYSPH @ISGLOBALorg @JVLazarus.bsky.social Loraxian #LiverTwitter
Today is the day! The @Nature #COVIDconsensus paper is now live at go.nature.com/3NtcfCM. All of our recommendations are 100% within human control and we need your help to spread the message to end #COVID19 as a #publichealth threat! #CovidTwitter

Recent expert commentary and the flagship event of the Global Think-Tank signal a long-overdue policy reckoning for chronic liver disease sldthinktank.com/policy_and_ins… #LiverTwitter #SLDthinktank @AASLDtweets @IntDiabetesFed @EASLEUAffairs @ncdalliance @WorldObesity @FattyLiverA

#IDF75- 65 days until our 75th anniversary! We continue our countdown to 23 September by looking back at some key moments in our history. In 1957, we established official relations with @WHO, the start of a long-standing collaboration that remains a core component of our work.…
Well, I guess @nickcave won't be repeating that exhibition. Was lucky to see it with my daughter at the Royal Library in Copenhagen... amazing donation of 2,000 books: theguardian.com/music/2025/jul…

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis @JVLazarus @TheLancet @geneyim @AlkhouriNaim pubmed.ncbi.nlm.nih.gov/40672054/
Two key points that we need to remember about the new SLD (Steatotic Liver Disease) nomenclature: 1️⃣ SLD ≠ MASLD — it also includes Alcohol-Related Liver Disease (ALD). 2️⃣ A person with metabolic syndrome + 10 drinks/day has ALD, not MetALD. @AASLDtweets @EASLedu @AEEHLiver
🔻🎉 ¡Ya han comenzado los #Sanfermines2025! #sanferminespamplona ¡Viva San Fermín! Gora San Fermín! ¡¡Felices fiestas!!
Excellent editorial in the @NEJM about the need to redefine clinical endpoints in MASH cirrhosis trials. With up to 25% of MASH patients already having cirrhosis at diagnosis, preventing decompensation & aiming for regression to non-cirrhotic stages is key.…
JUST OUT: "The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021)" In 2021, MASLD had a prevalence of 1.27 billion people while T2DM had a prevalence of 0.51 billion people worldwide. onlinelibrary.wiley.com/doi/10.1002/ue… #LiverTwitter @PojsakornDan
An important correspondence and here is our response nature.com/articles/s4157…. We need to continue to grow the MASLD community of practice. #LiverTwitter
New online! Pregnancy and liver health: delivering new collaborations to advance the MASLD and MASH field bit.ly/4lynBVT
New online! Reply to ‘Pregnancy and liver health: delivering new collaborations to advance the MASLD and MASH field’ bit.ly/4nnFrfK
🔝De Barcelona al mundo: un 'think tank' global sobre enfermedades hepáticas aparece en los titulares y entra en el registro científico. ¡Enhorabuena, compartimos! 👇
From Barcelona to the World: Global Think‑tank on Liver Disease Makes Headlines and Enters the Scientific Record sldthinktank.com/news/global-th… #SLDthinktank #LiverTwitter
Proud to see the outcomes of the Global Think-tank on Steatotic Liver Disease 2025 meeting in Barcelona featured in @TheLancet! Our multidisciplinary group tackled barriers to #MASLD diagnosis & care, with a spotlight on the urgent metabolic health threats. The story highlights…
Honoured to second author the most cited article in @HEP_Journal. Led by the great @marurinella and seniored by Dr Phil Newsome: journals.lww.com/hep/fulltext/2… #LiverTwitter
The 2024 Impact Factors are in, and we have good news! We're proud to share that the Impact Factor for @HEP_Journal—the leading scientific journal in #liverdisease—increased to 15.8. Check out the top 10 cited articles here: bit.ly/4lBhtw7 #Hepatology #AASLD
Important for #ADASciSessions - happening now in Chicago
Individuals with type 2 diabetes are at higher risk for clinically relevant liver disease. Could including liver health checks in annual diabetes reviews allow early interventions to prevent end-stage liver disease? thelancet.com/journals/langa… #LiverTwitter #WorldDiabetesDay
Honored to see the @TheAACE MASLD algorithm featured in the expert consensus statement on #MASLD from the Indian diabetologists' perspective. Grateful to contribute to advancing evidence-based care for MASLD globally! dom-pubs.onlinelibrary.wiley.com/doi/10.1111/do…
ICYMI: I was honored to participate in @EASLedu's recent online presentation, Steatotic Liver Disease Unpacked: Targeting Dynamic Risks. Watch here. #livertwitter @AleksanderKrag @MeenaBBansal #EASLStudio #LiverXhttps://bit.ly/3FWSvI3
We renamed a disease—not for science, but for people. 🩺 Proud to co-author the People-First Liver Charter alongside greats in @NaturePortfolio 🔗 nature.com/articles/s4159… Words can heal. Let’s end stigma in MASLD/MASH—across every specialty. 🌍💬